therapeutic agents (Beth Israel Deaconess Medical Center)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nametherapeutic agents (Beth Israel Deaconess Medical Center)
Drug Alias NameIL-23 targeting compounds (Beth Israel Deaconess Medical Center)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-23 modulators
TargetsInterleukin-23
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBeth Israel Deaconess Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeth Israel Deaconess Medical Center
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksN/A